Reading Room

FDA Alerts Consumers Concering Zicam®

Jon 8074

Jon L. Gelman LLC is investigating cases involving individuals who have suffered the loss of taste and smell (anosmia) after using Zicam®. Zicam® is an over-the-counter nasal spray used to relieve the symptoms associated with the common cold and flu and is manufactured by Matrixx Initiatives. Matrixx manufactures a range of products under the Zicam® name, but the name Zicam® is generally used to refer to its over-the-counter nasal zinc solution spray.  

Raptiva® Withdrawn From Market for High Risk of Fatal Brain Disease

Jon 6784

We are investigating cases in which Raptiva® users have experienced neurological changes including unusual weakness, loss of coordination and changes in vision.

On April 8, 2009, the drug manufacturer Genentech announced a phased withdrawal of the psoriasis drug Raptiva® (efalizumab) from the U.S. market.
 

Hydroxycut® Products Withdrawn From Market After FDA Consumer Advisory Warning

Jon 6556

Jon L. Gelman  is investigating potential cases involving users of Hydroxycut® products who have experienced health problems that may include Rhabdomyolysis (muscle damage that can lead to kidney failure and other health problems), death, cardiovascular symptoms, hypertension, elevated liver enzymes that can indicate liver failure, kidney failure and seizures. 

Fosamax Adverse Reactions

Jon 8591

Fosamax® (alendronate sodium tablets and oral solution) is a bisphosphonate manufactured by Merck, that is marketed, advertised, distributed and sold for the treatment of osteoporosis and Paget’s Disease. It has additionally been prescribed for off label uses such as bone cancers. Fosamax® tablets were approved by the FDA on September 29, 1995, while the oral solution was approved on September 17, 2003.

NuvaRing® Safety Labeling Changes

Jon 7767

NuvaRing® is a vaginal ring contraceptive medication that was approved by the FDA in October 2001. The drug is manufactured by Organon USA, Inc., based in New Jersey, which was acquired by Schering-Plough Corporation in 2007. Since its initial FDA approval and use on the market, NuvaRing® has been linked to serious venous thromboembolic events including blood clots, pulmonary embolism, stroke and myocardial infarction, or heart attack.
 

12

CONTACT US
1.973.696.7900
jon.gelman@gmail.com